Works matching AU Reck, Martin
Results: 90
Neue molekulare Therapien beim nichtkleinzelligen Lungenkarzinom am Beispiel der EGFR/HER1-Inhibition.
- Published in:
- Medizinische Klinik (Urban & Vogel), 2005, v. 100, n. 12, p. 785, doi. 10.1007/s00063-005-1130-1
- By:
- Publication type:
- Article
Randomized phase III trial of paclitaxel, etoposide, and carboplatin versus carboplatin, etoposide, and vincristine in patients with small-cell lung cancer.
- Published in:
- 2003
- By:
- Publication type:
- journal article
The Multi-Modal Effect of the Anti-fibrotic Drug Pirfenidone on NSCLC.
- Published in:
- Frontiers in Oncology, 2020, v. 9, p. 1, doi. 10.3389/fonc.2019.01550
- By:
- Publication type:
- Article
65Plus: open-label study of bevacizumab in combination with pemetrexed or pemetrexed/carboplatin as first-line treatment of patients with advanced or recurrent nonsquamous non-small-cell lung cancer.
- Published in:
- Lung Cancer: Targets & Therapy, 2017, v. 8, p. 217, doi. 10.2147/LCTT.S142972
- By:
- Publication type:
- Article
Efficacy and safety of bronchoscopic laser therapy in patients with tracheal and bronchial obstruction: a retrospective single institution report.
- Published in:
- Clinical Respiratory Journal, 2012, v. 6, n. 2, p. 67, doi. 10.1111/j.1752-699X.2011.00247.x
- By:
- Publication type:
- Article
Diagnostics and staging procedures in non-small cell lung cancer – is less more?
- Published in:
- Clinical Respiratory Journal, 2008, v. 2, n. 2, p. 67, doi. 10.1111/j.1752-699X.2008.00049.x
- By:
- Publication type:
- Article
RELAY, Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients with Untreated, Epidermal Growth Factor Receptor Mutation-Positive, Metastatic Non-Small-Cell Lung Cancer: Safety Profile and Manageability.
- Published in:
- Drug Safety, 2022, v. 45, n. 1, p. 45, doi. 10.1007/s40264-021-01127-2
- By:
- Publication type:
- Article
Comparative evaluation of PD‐L1 expression in cytology imprints, circulating tumour cells and tumour tissue in non‐small cell lung cancer patients.
- Published in:
- Molecular Oncology, 2023, v. 17, n. 5, p. 737, doi. 10.1002/1878-0261.13415
- By:
- Publication type:
- Article
Integrated circulating tumour DNA and cytokine analysis for therapy monitoring of ALK-rearranged lung adenocarcinoma.
- Published in:
- British Journal of Cancer, 2023, v. 129, n. 1, p. 112, doi. 10.1038/s41416-023-02284-0
- By:
- Publication type:
- Article
MDT-BRIDGE: Neoadjuvant Durvalumab Plus Chemotherapy Followed by Either Surgery and Adjuvant Durvalumab or Chemoradiotherapy and Consolidation Durvalumab in Resectable or Borderline-resectable Stage LIB-ILIB NSCLC.
- Published in:
- Clinical Lung Cancer, 2024, v. 25, n. 6, p. 587, doi. 10.1016/j.cllc.2024.06.007
- By:
- Publication type:
- Article
Molecular and Immune Biomarker Testing in Squamous-Cell Lung Cancer: Effect of Current and Future Therapies and Technologies.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Efficacy and Safety of Ramucirumab With Docetaxel Versus Placebo With Docetaxel as Second-Line Treatment of Advanced Non-Small-Cell Lung Cancer: A Subgroup Analysis According to Patient Age in the REVEL Trial.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Randomized, Double-Blind Phase Ib/III Study of Erlotinib With Ramucirumab or Placebo in Previously Untreated EGFR-Mutant Metastatic Non-Small-Cell Lung Cancer (RELAY): Phase Ib Results.
- Published in:
- 2018
- By:
- Publication type:
- journal article
LUME-Meso: Design and Rationale of the Phase III Part of a Placebo-Controlled Study of Nintedanib and Pemetrexed/Cisplatin Followed by Maintenance Nintedanib in Patients With Unresectable Malignant Pleural Mesothelioma.
- Published in:
- 2017
- By:
- Publication type:
- journal article
The APPLE Trial: Feasibility and Activity of AZD9291 (Osimertinib) Treatment on Positive PLasma T790M in EGFR-mutant NSCLC Patients. EORTC 1613.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Treatment Rationale and Study Design for the RELAY Study: A Multicenter, Randomized, Double-Blind Study of Erlotinib With Ramucirumab or Placebo in Patients With Epidermal Growth Factor Receptor Mutation- Positive Metastatic Non—Small-Cell Lung Cancer.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Treatment Rationale and Study Design for the JUNIPER Study: A Randomized Phase III Study of Abemaciclib With Best Supportive Care Versus Erlotinib With Best Supportive Care in Patients With Stage IV Non-Small-Cell Lung Cancer With a Detectable KRAS Mutation Whose Disease Has Progressed After Platinum-Based Chemotherapy.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Phase I Study of Lapatinib and Pemetrexed in the Second-Line Treatment of Advanced or Metastatic Non-Small-Cell Lung Cancer With Assessment of Circulating Cell Free Thymidylate Synthase RNA as a Potential Biomarker.
- Published in:
- 2015
- By:
- Publication type:
- journal article
Phase I Study of Lapatinib and Pemetrexed in the Second-Line Treatment of Advanced or Metastatic Non--Small-Cell Lung Cancer With Assessment of Circulating Cell Free Thymidylate Synthase RNA as a Potential Biomarker.
- Published in:
- Clinical Lung Cancer, 2015, v. 16, n. 5, p. 348, doi. 10.1016/j.cllc.2015.01.004
- By:
- Publication type:
- Article
Phase II Trial of Mapatumumab, a Fully Human Agonist Monoclonal Antibody to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptor 1 (TRAIL-R1), in Combination With Paclitaxel and Carboplatin in Patients With Advanced Non-Small-Cell Lung Cancer.
- Published in:
- 2014
- By:
- Publication type:
- Journal Article
Phase II Trial of Mapatumumab, a Fully Human Agonist Monoclonal Antibody to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptor 1 (TRAIL-R1), in Combination With Paclitaxel and Carboplatin in Patients With Advanced Non--Small-Cell Lung Cancer.
- Published in:
- Clinical Lung Cancer, 2014, v. 15, n. 3, p. 188, doi. 10.1016/j.cllc.2013.12.005
- By:
- Publication type:
- Article
A Randomized Phase II Study of Pemetrexed in Combination With Cisplatin or Carboplatin as First-Line Therapy for Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer.
- Published in:
- 2013
- By:
- Publication type:
- Journal Article
A Randomized Phase II Study of Pemetrexed in Combination With Cisplatin or Carboplatin as First-Line Therapy for Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer.
- Published in:
- Clinical Lung Cancer, 2013, v. 14, n. 3, p. 215, doi. 10.1016/j.cllc.2012.10.001
- By:
- Publication type:
- Article
Comparison of the sensitivity of different criteria to select lung cancer patients for screening in a cohort of German patients.
- Published in:
- Cancer Medicine, 2023, v. 12, n. 7, p. 8880, doi. 10.1002/cam4.5638
- By:
- Publication type:
- Article
Patient-reported outcomes in RELAY, a phase 3 trial of ramucirumab plus erlotinib versus placebo plus erlotinib in untreated EGFR-mutated metastatic non-small-cell lung cancer.
- Published in:
- Current Medical Research & Opinion, 2020, v. 36, n. 10, p. 1667, doi. 10.1080/03007995.2020.1808781
- By:
- Publication type:
- Article
Evaluation of changes in renal function in PARAMOUNT: a phase III study of maintenance pemetrexed plus best supportive care versus placebo plus best supportive care after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Efficacy of Docetaxel Plus Ramucirumab as Palliative Third-Line Therapy Following Second-Line Immune-Checkpoint-Inhibitor Treatment in Patients With Non-Small-Cell Lung Cancer Stage IV.
- Published in:
- Clinical Medicine Insights: Oncology, 2020, v. 14, p. 1, doi. 10.1177/1179554920951358
- By:
- Publication type:
- Article
Efficacy of Docetaxel Plus Ramucirumab as Palliative Third-Line Therapy Following Second-Line Immune-Checkpoint-Inhibitor Treatment in Patients With Non-Small-Cell Lung Cancer Stage IV.
- Published in:
- Clinical Medicine Insights: Oncology, 2020, v. 14, p. 1, doi. 10.1177/1179554920951358
- By:
- Publication type:
- Article
Change in non-small-cell lung cancer tumor size in patients treated with nintedanib plus docetaxel: analyses from the Phase III LUME-Lung 1 study.
- Published in:
- OncoTargets & Therapy, 2018, v. 11, p. 4573, doi. 10.2147/OTT.S170722
- By:
- Publication type:
- Article
DNA methylation profiles of bronchoscopic biopsies for the diagnosis of lung cancer.
- Published in:
- Clinical Epigenetics, 2021, v. 13, n. 1, p. 1, doi. 10.1186/s13148-021-01024-6
- By:
- Publication type:
- Article
Emerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancer.
- Published in:
- Journal of Hematology & Oncology, 2023, v. 16, n. 1, p. 1, doi. 10.1186/s13045-023-01464-y
- By:
- Publication type:
- Article
A Phase II Randomized Study of Cisplatin-Pemetrexed plus either Enzastaurin or Placebo in Chemonaive Patients with Advanced Non-Small Cell Lung Cancer.
- Published in:
- Oncology, 2012, v. 82, n. 1, p. 25, doi. 10.1159/000335268
- By:
- Publication type:
- Article
Clinical outcomes of ramucirumab plus docetaxel in the treatment of patients with non-small cell lung cancer after immunotherapy: a systematic literature review.
- Published in:
- Frontiers in Oncology, 2023, p. 01, doi. 10.3389/fonc.2023.1247879
- By:
- Publication type:
- Article
Patient-Reported Outcomes in Metastatic Nonsquamous Non--Small Cell Lung Cancer: PERLA Trial Comparing First-line Chemotherapy Plus Dostarlimab or Pembrolizumab.
- Published in:
- Journal of Oncology Navigation & Survivorship, 2023, v. 14, n. 11, p. 360
- By:
- Publication type:
- Article
CheckMate 227: Nivolumab + Ipilimumab vs Platinum-Doublet Chemotherapy as First-Line Treatment for Advanced Non--Small Cell Lung Cancer (NSCLC) with High Tumor Mutational Burden (TMB).
- Published in:
- Journal of Oncology Navigation & Survivorship, 2018, v. 9, p. 26
- By:
- Publication type:
- Article
Endobronchial Ultrasound with Transbronchial Needle Aspiration (EBUS-TBNA) in Patients with Negative Results in Conventional Bronchoscopy.
- Published in:
- Annals of Respiratory Medicine, 2011, v. 3, n. 1, p. 1
- By:
- Publication type:
- Article
Evaluation of atezolizumab immunogenicity: Efficacy and safety (Part 2).
- Published in:
- CTS: Clinical & Translational Science, 2022, v. 15, n. 1, p. 141, doi. 10.1111/cts.13149
- By:
- Publication type:
- Article
Phase 2, randomized, open-label study of ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non-small cell lung cancer.
- Published in:
- Cancer (0008543X), 2015, v. 121, n. 6, p. 883, doi. 10.1002/cncr.29132
- By:
- Publication type:
- Article
College Grade Point Average as a Predictor of Adult Success: A Reply.
- Published in:
- Public Personnel Management, 1989, v. 18, n. 2, p. 235, doi. 10.1177/009102608901800210
- By:
- Publication type:
- Article
TTF-1 is a highly sensitive but not fully specific marker for pulmonary and thyroidal cancer: a tissue microarray study evaluating more than 17,000 tumors from 152 different tumor entities.
- Published in:
- Virchows Archiv: European Journal of Pathology, 2024, v. 485, n. 5, p. 815, doi. 10.1007/s00428-024-03926-1
- By:
- Publication type:
- Article
Immuntherapie bei Lungenkrebs.
- Published in:
- Kompass Onkologie, 2016, v. 3, n. 2, p. 60, doi. 10.1159/000449440
- By:
- Publication type:
- Article
The Formal and Systematic Specification of Market Structures and Trading Services.
- Published in:
- Journal of Management Information Systems, 1998, v. 15, n. 2, p. 9, doi. 10.1080/07421222.1998.11518206
- By:
- Publication type:
- Article
Longitudinal monitoring of cell-free DNA methylation in ALK-positive non-small cell lung cancer patients.
- Published in:
- Clinical Epigenetics, 2022, v. 14, n. 1, p. 1, doi. 10.1186/s13148-022-01387-4
- By:
- Publication type:
- Article
In Reply.
- Published in:
- Deutsches Ärzteblatt International, 2023, v. 120, n. 41, p. 3, doi. 10.3238/arztebl.m2023.0198
- By:
- Publication type:
- Article
Lung Cancer Screening With Low-Dose Computed Tomography.
- Published in:
- Deutsches Ärzteblatt International, 2023, v. 120, n. 23, p. 387, doi. 10.3238/arztebl.m2023.0099
- By:
- Publication type:
- Article
Characterizing death acceptance among patients with cancer.
- Published in:
- 2019
- By:
- Publication type:
- journal article
The Validity of Job Knowledge Measures.
- Published in:
- International Journal of Selection & Assessment, 1993, v. 1, n. 3, p. 153, doi. 10.1111/j.1468-2389.1993.tb00103.x
- By:
- Publication type:
- Article
Perceived relatedness, death acceptance, and demoralization in patients with cancer.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Risk Assessment for Patients with Chronic Respiratory Conditions in the Context of the SARS-CoV-2 Pandemic Statement of the German Respiratory Society with the Support of the German Association of Chest Physicians.
- Published in:
- Respiration, 2022, v. 101, n. 3, p. 307, doi. 10.1159/000518896
- By:
- Publication type:
- Article
Fountain of youth for squamous cell carcinomas? On the epigenetic age of non‐small cell lung cancer and corresponding tumor‐free lung tissues.
- Published in:
- International Journal of Cancer, 2018, v. 143, n. 12, p. 3061, doi. 10.1002/ijc.31641
- By:
- Publication type:
- Article